clonidine, levobupivacaine — Competitive Intelligence Brief

clonidine, levobupivacaine (clonidine, levobupivacaine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with adjuvant alpha-2 agonist. Area: Anesthesia and Pain Management.

marketed Local anesthetic with adjuvant alpha-2 agonist Alpha-2 adrenergic receptor (clonidine); voltage-gated sodium channels (levobupivacaine) Anesthesia and Pain Management Small molecule

Target snapshot

clonidine, levobupivacaine (clonidine, levobupivacaine) — University Hospital Dubrava. Clonidine is an alpha-2 adrenergic agonist that reduces pain signaling, while levobupivacaine is a local anesthetic that blocks sodium channels to prevent nerve conduction.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
clonidine, levobupivacaine TARGET	clonidine, levobupivacaine	University Hospital Dubrava	marketed	Local anesthetic with adjuvant alpha-2 agonist	Alpha-2 adrenergic receptor (clonidine); voltage-gated sodium channels (levobupivacaine)
ropivacaine plus clonidine	ropivacaine plus clonidine	University Hospital, Lille	marketed	Local anesthetic with adjuvant alpha-2 agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (clonidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with adjuvant alpha-2 agonist class)

1. University Hospital Dubrava · 1 drug in this class
2. University Hospital, Lille · 1 drug in this class